Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Item
http://www.wikidata.org/entity/Q42124738
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyA highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.Targeting the tumor microenvironment to enhance antitumor immune responsesA core of kinase-regulated interactomes defines the neoplastic MDSC lineage.Drafting the proteome landscape of myeloid-derived suppressor cells.Novel immunotherapies for the treatment of melanoma.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.Myeloid-derived suppressor cells as effectors of immune suppression in cancer.Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.PD1 signal transduction pathways in T cells.The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.The intracellular signalosome of PD-L1 in cancer cellsTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Item
http://www.wikidata.org/entity/Q42124738
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@en
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@nl
type
label
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@en
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@nl
prefLabel
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@en
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Anti-melanoma vaccines enginee ...... adout of therapeutic efficacy.
@en
P2093
P2860
P304
P31
P356
10.4161/21624011.2014.945378
P433
P478
P50
P577
P5875
P698
P932